Single-Sample Biomarker Diagnosis for At-Risk NASH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-invasive tests for nonalcoholic steatohepatitis (NASH) are inadequate for early detection, particularly for identifying at-risk populations with high risk of liver complications, due to technical limitations and risks associated with biopsies, and existing blood-based tests require multiple biological fluids and processes.
Innovation Solution
A method involving the quantification of miR-34a-5p and YKL-40 levels in a biological fluid sample, combined with the subject's gender, using a mathematical function to predict the risk of NASH through a logistic regression model, allowing for a simplified and robust diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liver biopsy is used as the clinical reference standard for diagnosis of NASH and fibrosis, then diagnostic accuracy is improved, but technical limitations and risks increase
Solution Approach 1:
The patent uses blood-based biomarkers (miR-34a-5p, A2M, YKL-40, HbA1c) as intermediary substances to indirectly assess liver condition without direct tissue sampling. These biomarkers serve as mediators that reflect liver pathology states, enabling diagnosis while avoiding biopsy-related harms.
Solution Approach 2:
The invention replaces the mechanical invasive procedure of liver biopsy with a non-invasive blood test system. The mechanical needle puncture and tissue extraction are substituted by simple blood sampling combined with biomarker quantification, eliminating physical trauma while maintaining diagnostic capability.
2Reliability
If NIS4 test uses 4 different biomarkers requiring different biological fluids and lab processes, then diagnostic robustness is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple biomarker assessments into a single integrated test system that uses only serum samples. The four biomarkers (miR-34a-5p, A2M, YKL-40, HbA1c) are simultaneously measured in one biological fluid using a unified laboratory protocol, combining diagnostic power while simplifying operational complexity.
Solution Approach 2:
The invention creates a universal test platform where a single serum sample serves multiple diagnostic purposes by measuring all four biomarkers. This multi-functional approach allows one sample type and one lab process to fulfill comprehensive diagnostic requirements that previously demanded multiple specialized procedures.
3Measurement precision
If existing blood-based NITs are developed mainly to fit with fibrosis stages, then fibrosis detection capability is improved, but ability to detect at-risk NASH population is reduced
Solution Approach 1:
The patent employs a composite diagnostic approach combining four different biomarker types (microRNA, protein, glycoprotein, and glycated hemoglobin) that collectively assess both fibrosis stage and NASH activity. This composite biomarker panel provides comprehensive evaluation of liver pathology, detecting at-risk populations with NAS≥4 and F≥2 while maintaining fibrosis detection accuracy.
Data Source
AI summary
The present invention provides improved methods for the diagnosis of at-risk NASH.